Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease Inhibitors

Re-examination of the design of the cyclic urea class of HIV protease (HIVPR) inhibitors suggests a general approach to designing novel nonpeptide cyclic HIVPR inhibitors. This process involves the inversion of the stereochemical centers of the core transition-state isostere of the linear HIVPR inhi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1997-05, Vol.40 (11), p.1707-1719
Hauptverfasser: De Lucca, George V, Liang, Jing, Aldrich, Paul E, Calabrese, Joe, Cordova, Beverly, Klabe, Ronald M, Rayner, Marlene M, Chang, Chong-Hwan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1719
container_issue 11
container_start_page 1707
container_title Journal of medicinal chemistry
container_volume 40
creator De Lucca, George V
Liang, Jing
Aldrich, Paul E
Calabrese, Joe
Cordova, Beverly
Klabe, Ronald M
Rayner, Marlene M
Chang, Chong-Hwan
description Re-examination of the design of the cyclic urea class of HIV protease (HIVPR) inhibitors suggests a general approach to designing novel nonpeptide cyclic HIVPR inhibitors. This process involves the inversion of the stereochemical centers of the core transition-state isostere of the linear HIVPR inhibitors and cyclization of the resulting core using an appropriate cyclizing reagent. As an example, this process is applied to the diamino alcohol class of HIVPR inhibitors11 to give tetrahydropyrimidinones. Conformational analysis of the tetrahydropyrimidinones and modeling of its interaction with the active site of HIVPR suggested modifications which led to very potent inhibitors of HIVPR (24 with a K i = 0.018 nM). The X-ray crystallographic structure of the complex of 24 with HIVPR confirms the analysis and modeling predictions. The example reported in this study and other examples that are cited indicate that this process may be generally applicable to other linear inhibitors.
doi_str_mv 10.1021/jm970081i
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16014469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16014469</sourcerecordid><originalsourceid>FETCH-LOGICAL-a377t-8138ba6aec5211c19c1a78407370461fb1549545dd910e5dad857dbfe82440333</originalsourceid><addsrcrecordid>eNpt0N1qFDEUB_AgSt1WL3wAIRcqCB3N18xkLkvd3S4UrXT1NpyZZNyss8mYZEr3BXxuU3bZKyFwAufH4Zw_Qm8o-UQJo5-3u6YmRFL7DM1oyUghJBHP0YwQxgpWMf4Snce4JYRwyvgZOmtoTaUkM_T3i4n2l7vE93uXNvkfLzE4jecPMEyQrHfY93htUoDNXgc_7oPdWW2ddyZiyM_h-SPsxsE8QcBL40yAAV-NY_DQbXDy-Kt3oxmT1QbfrH7iu-CTgWjwym1sa5MP8RV60cMQzetjvUA_FvP19U1x-225ur66LYDXdSok5bKFCkxXMko72nQUailIzWsiKtq3tBRNKUqtG0pMqUHLstZtbyQTgnDOL9CHw9y83J_JxKR2NnZmGMAZP0VFK0KFqJoMPx5gF3yMwfRqzIdD2CtK1FPm6pR5tm-PQ6d2Z_RJHkPO_XfHPsQOhj6A62w8MVZJzhuZWXFgNibzeGpD-K2qfGCp1nf3qq7E4nsjFmqZ_fuDhy6qrZ-Cy8n9Z71_x0akMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16014469</pqid></control><display><type>article</type><title>Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease Inhibitors</title><source>ACS Publications</source><source>MEDLINE</source><creator>De Lucca, George V ; Liang, Jing ; Aldrich, Paul E ; Calabrese, Joe ; Cordova, Beverly ; Klabe, Ronald M ; Rayner, Marlene M ; Chang, Chong-Hwan</creator><creatorcontrib>De Lucca, George V ; Liang, Jing ; Aldrich, Paul E ; Calabrese, Joe ; Cordova, Beverly ; Klabe, Ronald M ; Rayner, Marlene M ; Chang, Chong-Hwan</creatorcontrib><description>Re-examination of the design of the cyclic urea class of HIV protease (HIVPR) inhibitors suggests a general approach to designing novel nonpeptide cyclic HIVPR inhibitors. This process involves the inversion of the stereochemical centers of the core transition-state isostere of the linear HIVPR inhibitors and cyclization of the resulting core using an appropriate cyclizing reagent. As an example, this process is applied to the diamino alcohol class of HIVPR inhibitors11 to give tetrahydropyrimidinones. Conformational analysis of the tetrahydropyrimidinones and modeling of its interaction with the active site of HIVPR suggested modifications which led to very potent inhibitors of HIVPR (24 with a K i = 0.018 nM). The X-ray crystallographic structure of the complex of 24 with HIVPR confirms the analysis and modeling predictions. The example reported in this study and other examples that are cited indicate that this process may be generally applicable to other linear inhibitors.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm970081i</identifier><identifier>PMID: 9171880</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Binding Sites ; Biological and medical sciences ; Computer Simulation ; Crystallography, X-Ray ; Cyclization ; Drug Design ; HIV Protease Inhibitors - chemical synthesis ; HIV Protease Inhibitors - chemistry ; HIV Protease Inhibitors - pharmacology ; Human immunodeficiency virus ; Hydrogen Bonding ; Medical sciences ; Models, Molecular ; Molecular Conformation ; Molecular Structure ; Oximes - chemical synthesis ; Oximes - chemistry ; Oximes - pharmacology ; Pharmacology. Drug treatments ; Pyrimidinones - chemical synthesis ; Pyrimidinones - chemistry ; Pyrimidinones - pharmacology</subject><ispartof>Journal of medicinal chemistry, 1997-05, Vol.40 (11), p.1707-1719</ispartof><rights>Copyright © 1997 American Chemical Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a377t-8138ba6aec5211c19c1a78407370461fb1549545dd910e5dad857dbfe82440333</citedby><cites>FETCH-LOGICAL-a377t-8138ba6aec5211c19c1a78407370461fb1549545dd910e5dad857dbfe82440333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm970081i$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm970081i$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2683398$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9171880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Lucca, George V</creatorcontrib><creatorcontrib>Liang, Jing</creatorcontrib><creatorcontrib>Aldrich, Paul E</creatorcontrib><creatorcontrib>Calabrese, Joe</creatorcontrib><creatorcontrib>Cordova, Beverly</creatorcontrib><creatorcontrib>Klabe, Ronald M</creatorcontrib><creatorcontrib>Rayner, Marlene M</creatorcontrib><creatorcontrib>Chang, Chong-Hwan</creatorcontrib><title>Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease Inhibitors</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Re-examination of the design of the cyclic urea class of HIV protease (HIVPR) inhibitors suggests a general approach to designing novel nonpeptide cyclic HIVPR inhibitors. This process involves the inversion of the stereochemical centers of the core transition-state isostere of the linear HIVPR inhibitors and cyclization of the resulting core using an appropriate cyclizing reagent. As an example, this process is applied to the diamino alcohol class of HIVPR inhibitors11 to give tetrahydropyrimidinones. Conformational analysis of the tetrahydropyrimidinones and modeling of its interaction with the active site of HIVPR suggested modifications which led to very potent inhibitors of HIVPR (24 with a K i = 0.018 nM). The X-ray crystallographic structure of the complex of 24 with HIVPR confirms the analysis and modeling predictions. The example reported in this study and other examples that are cited indicate that this process may be generally applicable to other linear inhibitors.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Computer Simulation</subject><subject>Crystallography, X-Ray</subject><subject>Cyclization</subject><subject>Drug Design</subject><subject>HIV Protease Inhibitors - chemical synthesis</subject><subject>HIV Protease Inhibitors - chemistry</subject><subject>HIV Protease Inhibitors - pharmacology</subject><subject>Human immunodeficiency virus</subject><subject>Hydrogen Bonding</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Conformation</subject><subject>Molecular Structure</subject><subject>Oximes - chemical synthesis</subject><subject>Oximes - chemistry</subject><subject>Oximes - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrimidinones - chemical synthesis</subject><subject>Pyrimidinones - chemistry</subject><subject>Pyrimidinones - pharmacology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0N1qFDEUB_AgSt1WL3wAIRcqCB3N18xkLkvd3S4UrXT1NpyZZNyss8mYZEr3BXxuU3bZKyFwAufH4Zw_Qm8o-UQJo5-3u6YmRFL7DM1oyUghJBHP0YwQxgpWMf4Snce4JYRwyvgZOmtoTaUkM_T3i4n2l7vE93uXNvkfLzE4jecPMEyQrHfY93htUoDNXgc_7oPdWW2ddyZiyM_h-SPsxsE8QcBL40yAAV-NY_DQbXDy-Kt3oxmT1QbfrH7iu-CTgWjwym1sa5MP8RV60cMQzetjvUA_FvP19U1x-225ur66LYDXdSok5bKFCkxXMko72nQUailIzWsiKtq3tBRNKUqtG0pMqUHLstZtbyQTgnDOL9CHw9y83J_JxKR2NnZmGMAZP0VFK0KFqJoMPx5gF3yMwfRqzIdD2CtK1FPm6pR5tm-PQ6d2Z_RJHkPO_XfHPsQOhj6A62w8MVZJzhuZWXFgNibzeGpD-K2qfGCp1nf3qq7E4nsjFmqZ_fuDhy6qrZ-Cy8n9Z71_x0akMA</recordid><startdate>19970523</startdate><enddate>19970523</enddate><creator>De Lucca, George V</creator><creator>Liang, Jing</creator><creator>Aldrich, Paul E</creator><creator>Calabrese, Joe</creator><creator>Cordova, Beverly</creator><creator>Klabe, Ronald M</creator><creator>Rayner, Marlene M</creator><creator>Chang, Chong-Hwan</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19970523</creationdate><title>Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease Inhibitors</title><author>De Lucca, George V ; Liang, Jing ; Aldrich, Paul E ; Calabrese, Joe ; Cordova, Beverly ; Klabe, Ronald M ; Rayner, Marlene M ; Chang, Chong-Hwan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a377t-8138ba6aec5211c19c1a78407370461fb1549545dd910e5dad857dbfe82440333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Computer Simulation</topic><topic>Crystallography, X-Ray</topic><topic>Cyclization</topic><topic>Drug Design</topic><topic>HIV Protease Inhibitors - chemical synthesis</topic><topic>HIV Protease Inhibitors - chemistry</topic><topic>HIV Protease Inhibitors - pharmacology</topic><topic>Human immunodeficiency virus</topic><topic>Hydrogen Bonding</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Conformation</topic><topic>Molecular Structure</topic><topic>Oximes - chemical synthesis</topic><topic>Oximes - chemistry</topic><topic>Oximes - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrimidinones - chemical synthesis</topic><topic>Pyrimidinones - chemistry</topic><topic>Pyrimidinones - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Lucca, George V</creatorcontrib><creatorcontrib>Liang, Jing</creatorcontrib><creatorcontrib>Aldrich, Paul E</creatorcontrib><creatorcontrib>Calabrese, Joe</creatorcontrib><creatorcontrib>Cordova, Beverly</creatorcontrib><creatorcontrib>Klabe, Ronald M</creatorcontrib><creatorcontrib>Rayner, Marlene M</creatorcontrib><creatorcontrib>Chang, Chong-Hwan</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Lucca, George V</au><au>Liang, Jing</au><au>Aldrich, Paul E</au><au>Calabrese, Joe</au><au>Cordova, Beverly</au><au>Klabe, Ronald M</au><au>Rayner, Marlene M</au><au>Chang, Chong-Hwan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease Inhibitors</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1997-05-23</date><risdate>1997</risdate><volume>40</volume><issue>11</issue><spage>1707</spage><epage>1719</epage><pages>1707-1719</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Re-examination of the design of the cyclic urea class of HIV protease (HIVPR) inhibitors suggests a general approach to designing novel nonpeptide cyclic HIVPR inhibitors. This process involves the inversion of the stereochemical centers of the core transition-state isostere of the linear HIVPR inhibitors and cyclization of the resulting core using an appropriate cyclizing reagent. As an example, this process is applied to the diamino alcohol class of HIVPR inhibitors11 to give tetrahydropyrimidinones. Conformational analysis of the tetrahydropyrimidinones and modeling of its interaction with the active site of HIVPR suggested modifications which led to very potent inhibitors of HIVPR (24 with a K i = 0.018 nM). The X-ray crystallographic structure of the complex of 24 with HIVPR confirms the analysis and modeling predictions. The example reported in this study and other examples that are cited indicate that this process may be generally applicable to other linear inhibitors.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>9171880</pmid><doi>10.1021/jm970081i</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1997-05, Vol.40 (11), p.1707-1719
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_16014469
source ACS Publications; MEDLINE
subjects Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Binding Sites
Biological and medical sciences
Computer Simulation
Crystallography, X-Ray
Cyclization
Drug Design
HIV Protease Inhibitors - chemical synthesis
HIV Protease Inhibitors - chemistry
HIV Protease Inhibitors - pharmacology
Human immunodeficiency virus
Hydrogen Bonding
Medical sciences
Models, Molecular
Molecular Conformation
Molecular Structure
Oximes - chemical synthesis
Oximes - chemistry
Oximes - pharmacology
Pharmacology. Drug treatments
Pyrimidinones - chemical synthesis
Pyrimidinones - chemistry
Pyrimidinones - pharmacology
title Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease Inhibitors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T18%3A12%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20Synthesis,%20and%20Evaluation%20of%20Tetrahydropyrimidinones%20as%20an%20Example%20of%20a%20General%20Approach%20to%20Nonpeptide%20HIV%20Protease%20Inhibitors&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=De%20Lucca,%20George%20V&rft.date=1997-05-23&rft.volume=40&rft.issue=11&rft.spage=1707&rft.epage=1719&rft.pages=1707-1719&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm970081i&rft_dat=%3Cproquest_cross%3E16014469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16014469&rft_id=info:pmid/9171880&rfr_iscdi=true